Greenlight Capital Re reports today against a quietly uncomfortable backdrop: the stock has fallen 7.5% over the past week, and the insiders who know the business best have been consistent sellers all summer.
The insider selling is the standout story here. Multiple insiders have sold shares across June and into late June — an Independent Director offloaded stock across five separate sessions between June 22 and June 29, while the COO sold in the same window. A second Independent Director was selling aggressively in May, unloading more than 47,000 shares across three transactions at prices ranging from $16.87 to $18.01. Net insider activity over the trailing 90 days totals a disposal of roughly $1.5 million in value. None of these trades carry high significance scores individually, but the pattern — multiple insiders, multiple sessions, across two months — is worth noting as the company steps up to report.
The broader positioning picture is far from extreme, which makes the insider activity the clearest signal available. Short interest is modest at 1.9% of the free float and has been drifting lower — down roughly 6% on the week. Borrow availability is exceptionally loose at nearly 3,000%, meaning there is no shortage of shares for new shorts to work with and no squeeze dynamic in play. The cost to borrow is negligible at 0.64%. On options, the put/call ratio sits at 0.03 — well below any level that would suggest defensive positioning — and has barely moved in weeks. The stock is thinly traded on the options market, so reading too much into PCR here would be a stretch. Taken together, the lending and options data describe a name where there is no crowded short thesis, no hedging surge, and no borrow pressure.
The valuation angle offers some context for the bulls. The stock trades at roughly 0.66x book — a discount that historically attracts value-oriented buyers in reinsurance. Earnings history from the two most recent prints shows very limited post-result moves: both the May 2026 and the prior quarter landed with barely half a percent of day-one movement, drifting only slightly further over five sessions. That pattern suggests the market has not been treating GLRE as a high-volatility earnings event. The institutional register anchors the stock further — DME 2022 Holdings holds nearly 15% of shares, and David Einhorn personally holds over 4%, meaning the closely-held structure limits dramatic float-driven swings. BlackRock added shares last quarter, and American Century built a meaningful new position.
Today's print will test whether the operational reinsurance results can offer a counternarrative to the insider selling trend — and whether a below-book valuation is enough to keep the stock from extending its recent weekly decline.
See the live data behind this article on ORTEX.
Open GLRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
